In a recent legal update, Astellas Pharma’s bid to hinder the launch of generic drugs competing with its leading overactive bladder medication has met with defeat. On Thursday, the Federal Circuit ruled against Astellas Pharma, revoking a temporary prohibition the appeals court instituted in April.
The Japanese multinational pharmaceutical company had strived extensively to safeguard its highly profitable overactive bladder drug from potential generic counterparts. However, the Federal Circuit’s latest decision seems to tip the scales in favor of the generic drug companies.
On hearing the court’s judgement, implications for the pharmaceutical industry could be significant. Generic drugs typically offer affordable alternatives for patients across a wide income bracket; however, they pose significant challenges for research and innovation-intensive companies like Astellas Pharma.
The exact legal sequences of events leading to the Federal Circuit’s lifting of the ban and the potential repercussions for global pharma business are detailed in the Law360 report.